Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study
Sign Up to like & getrecommendations! Published in 2022 at "Circulation. Genomic and Precision Medicine"
DOI: 10.1161/circgen.122.003730
Abstract: Background: Lamin A/C gene (LMNA)-related dilated cardiomyopathy is a serious and life-threatening condition with a high unmet medical need. This phase 2 study assessed the effects of the oral selective p38 mitogen-activated protein kinase inhibitor… read more here.
Keywords: arry 371797; lmna related; related dilated; phase study ... See more keywords
Plain Language Summary of Publication of the safety and efficacy of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene.
Sign Up to like & getrecommendations! Published in 2023 at "Future cardiology"
DOI: 10.2217/fca-2022-0099
Abstract: WHAT IS THIS PLAIN LANGUAGE SUMMARY ABOUT? This plain language summary describes the results of a study looking at the effects of a medicine called ARRY-371797 (also known as PF-07265803) in people with dilated cardiomyopathy… read more here.
Keywords: arry 371797; lmna gene; faulty lmna; heart ... See more keywords
Long-term effectiveness of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene: a plain language summary.
Sign Up to like & getrecommendations! Published in 2023 at "Future cardiology"
DOI: 10.2217/fca-2022-0125
Abstract: WHAT IS THIS PLAIN LANGUAGE SUMMARY ABOUT? This summary explains the results of a long-term extension study on the effects of a specific medicine. A long-term extension study allows people who have already completed a… read more here.
Keywords: long term; arry 371797; extension study; treatment ... See more keywords